The Globe and Mail reports in its Tuesday, July 18, edition that RBC Capital analyst Irene Nattel has reaffirmed her "outperform" recommendation for Park Lawn. The Globe's Darcy Keith writes in the Eye On Equities column that Ms. Nattel gave her share target a $5 trim to $36. Analysts on average target the shares at $34.31. The Globe says she cut her share target because of a recent decline in the U.S. death rate. Ms. Nattel, however, says she believes business is starting to normalize. Ms. Nattel says in a note: "Channel checks indicate the decline in the U.S. death rate normalized sequentially from negative 13 per cent Y/Y in Q1 to negative 8 per cent in Q2. While normalizing death rates from pandemic highs continue to muddle near-term visibility, COVID distortions should ease as we move through 2023." Mr. Keith says she also notes a couple of other negatives for the death care services company at the moment: tighter consumer spending impacting preneed sales, and the high fixed cost nature of the company, which is impacting operating leverage. The Globe reported on March 22 that Stifel analyst Martin Landry rated Park Lawn "buy." It was then worth $28.19.